Protagonist Therapeutics filings document formal disclosures for a biopharmaceutical company built around peptide therapeutics. Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations and material event exhibits tied to pipeline, collaboration and operating developments.
Proxy and annual meeting filings describe board elections, executive compensation votes, auditor ratification, equity incentive plan matters, stockholder voting results and the company's common stock voting structure. These records also frame governance, compensation and capital-related disclosures for Protagonist's Nasdaq-listed Delaware corporation.
Protagonist Therapeutics President and CEO Dinesh V. Patel reported an exercise-and-sale transaction involving 75,000 shares of common stock. On May 12, 2026, he exercised stock options for 75,000 shares at $21.58 per share and sold 75,000 shares in open-market trades at a weighted average price of $100.12 per share, with individual sale prices ranging from $98.83 to $103.50. After these transactions, he directly holds 523,478 common shares. The filing notes the actions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on January 30, 2026, and that the related stock options are fully vested and expire on October 11, 2026, with 225,000 options reported as remaining outstanding.
Protagonist Therapeutics, Inc. President and CEO Dinesh V. Patel reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 75,000 shares of common stock at an exercise price of $21.58 per share, then sold 75,000 shares in an open-market transaction at a weighted average price of $100.12 per share across multiple trades ranging from $98.83 to $103.50. Following these transactions, he directly holds 523,478 shares of common stock. The exercised stock options were fully vested and are scheduled to expire on October 11, 2026.
PTGX insider sale notice: A Form 144 filing states 75,000 shares of Common Stock are to be sold on 05/12/2026 in connection with an Option Exercise for cash. The filing also reports prior sales of 54,641 shares on 03/25/2026 by Dinesh Patel.
State Street Corporation reported beneficial ownership of 3,116,804 shares of Protagonist Therapeutics Inc. The filing, a Schedule 13G, shows 4.9% of the class and discloses shared voting power of 2,956,605 and shared dispositive power of 3,116,804. The filing lists related State Street entities and was signed by a Senior Vice President on 05/12/2026.
Protagonist Therapeutics director Bryan Giraudo reported exercising stock options and selling shares of common stock. On May 7, he exercised options for 36,000 shares at exercise prices of $6.45 and $6.98 per share and sold 36,000 directly held shares at about $100.14 per share. The Bryan & Courtney Giraudo Trust sold an additional 12,000 shares that day at about $100.07 per share.
On May 8, Giraudo sold 5,130 directly held shares at $100.00 per share, and the trust sold another 6,000 shares at $100.00 per share. A footnote states these sales occurred at prices ranging from $98.69 to $104.67. After these transactions, he holds 12,695 shares of Protagonist Therapeutics common stock directly, and the trust no longer holds shares from these reported transactions. All reported stock options are shown as fully exercised, with no remaining derivative holdings in this filing.
Bryan M. Giraudo and Bryan M. & Courtney L. Giraudo reported dispositions of Common stock in a Form 144 related to PTGX. The filing shows sales on 05/07/2026: 12,000 shares by Bryan M. & Courtney L. Giraudo for $1,200,873.60 and 36,000 shares by Bryan M. Giraudo for $3,604,968.00. The record lists prior compensation issuances of 6,000 shares (12/03/2019) and 5,130 shares (01/15/2026) under issuer compensation entries.
PTGX reported a Form 144 notice indicating proposed sales of 12,000 shares of Common Stock. The filing lists two compensation-related lots of Common stock — 10,000 shares dated 05/16/2018 and 2,000 shares dated 12/03/2019. The form shows a value figure of $1,200,873.60 and an entry 05/07/2026 associated with the NASDAQ listing.
Protagonist Therapeutics reported a profitable first quarter of 2026 driven by collaboration milestones and a strong cash position. License and collaboration revenue reached $56.4 million, nearly doubling from the prior year period, mainly from a $50.0 million FDA-approval milestone for ICOTYDE, its oral psoriasis drug partnered with JNJ.
The company generated net income of $3.8 million, compared with a loss of $11.7 million a year earlier, as milestone revenue more than offset higher research and development spending of $46.7 million. General and administrative expenses rose to $13.3 million, reflecting headcount and stock-based compensation growth.
Cash, cash equivalents and marketable securities totaled about $620.3 million at March 31, 2026, providing substantial funding for its pipeline in inflammation, hematology and metabolic diseases. After quarter-end, Protagonist exercised its opt-out right in the Takeda rusfertide deal, triggering a $200.0 million payment and shifting the arrangement to a global royalty and milestone model.
Protagonist Therapeutics posted a profitable first quarter of 2026 while securing major regulatory and partnership milestones. License and collaboration revenue reached $56.4 million, up from $28.3 million a year earlier, driving net income of $3.8 million versus a prior-period net loss of $11.7 million.
ICOTYDE received U.S. FDA approval for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment and positioning Protagonist to earn up to $580 million more in milestones plus 6%–10% tiered royalties. Rusfertide’s NDA was accepted with Priority Review and a PDUFA goal date in August 2026.
By opting out of the U.S. profit and loss sharing with Takeda for rusfertide, Protagonist unlocked a $200 million payment, with eligibility for an additional $200 million opt-out fee, a $75 million approval milestone, and up to $775 million in sales milestones, alongside 14%–29% worldwide royalties. Cash, cash equivalents and marketable securities totaled $620 million as of March 31, 2026, which the company expects to fund operations through at least 2028.